Home » Topics » BioWorld Science, Conferences

BioWorld Science, Conferences
RSS

New details disclosed on phase I cenderitide trial

March 30, 2012

Anacetrapib improves dyslipidemia in Japanese trial

March 30, 2012

Researchers at Vertex Pharmaceuticals identify new selective PLK1 inhibitor

March 30, 2012

Lexicon Pharmaceuticals provides first description of early development of LX-4211

March 30, 2012

Search for novel triple reuptake inhibitors yields ALB-109780

March 29, 2012

Notch mRNA signature biomarker monitors effects of PS-1-selective GSI

March 29, 2012

German study links new gene to atherosclerosis

March 28, 2012

New diacylglycerol O-acyltransferase 1 inhibitors show promise to treat metabolic diseases

March 28, 2012

Beneficial effects seen with ETC-1002 in patients with hypercholesterolemia

March 28, 2012

Novel 2-spiro-proline derivative inhibits 11-beta-HSD1

March 28, 2012

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
ADEL wins $1.04B Sanofi deal for tau-targeting Alzheimer’s drug
BioWorld
ADEL Inc. closed a year-end licensing deal worth up to $1.04 billion with Sanofi SA for ADEL-Y01, a specific tau-targeting Alzheimer’s disease drug candidate in a...